(Q37777492)

23 August 2017

1 reference

title

Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer (English)

1 reference

23 August 2017

Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

16 June 2024

1 reference

1 reference

1

Fred Saad

1 reference

23 August 2017

James A. Eastham

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682371

16 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20682371

16 June 2024

publication date

1 June 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0093775410000801?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

https://api.elsevier.com/content/article/PII:S0093775410000801?httpAccept=text/plain

16 June 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

16 June 2024

1 reference

23 August 2017

volume

37 Suppl 1

1 reference

23 August 2017

page(s)

S38-44

1 reference

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

23 August 2017

cites work

Cancer statistics, 2009

1 reference

28 May 2022

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

2

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

16 June 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Metastasis to bone: causes, consequences and therapeutic opportunities

16 June 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Metastatic transitional cell carcinoma from the bladder: radiographic manifestions

16 June 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

16 June 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

16 June 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

16 June 2024

Burden of bone disease

9

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

16 June 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

16 June 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

16 June 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

16 June 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

16 June 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature

16 June 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy

16 June 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Bladder carcinoma as a systemic disease

16 June 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma.

16 June 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

16 June 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease

16 June 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

16 June 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity

16 June 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

16 June 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity

16 June 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Antitumor effects of bisphosphonates: promising preclinical evidence

16 June 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines

16 June 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model

16 June 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model

16 June 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

16 June 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.001

16 June 2024

Identifiers

1 reference

23 August 2017

1 reference